Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04152200
Other study ID # ALN-GO1-005
Secondary ID 2019-001346-1720
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date January 21, 2020
Est. completion date July 2025

Study information

Verified date May 2024
Source Alnylam Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in patients with Advanced Primary Hyperoxaluria Type 1 (PH1).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 21
Est. completion date July 2025
Est. primary completion date May 18, 2021
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Has documented diagnosis of primary hyperoxaluria type 1 (PH1) - Estimated glomerular filtration rate (eGFR) =45 mL/min/1.73 m^2 for patients =12 months of age (<12 months of age, must have serum creatinine considered elevated for age) - Meets plasma oxalate level requirements - If taking Vitamin B6 (pyridoxine), must have been on stable regimen for at least 90 days - If on dialysis, may be on hemodialysis therapy only and must have been on a stable regimen for at least 4 weeks Exclusion Criteria: - Hemodialysis/peritoneal dialysis combination therapy or peritoneal dialysis alone - Diagnosis of conditions other than PH1 contributing to renal insufficiency - History of liver transplant - History of kidney transplant and currently receiving immunosuppressants

Study Design


Intervention

Drug:
Lumasiran
Lumasiran will be administered by subcutaneous (SC) injection.

Locations

Country Name City State
Australia Clinical Trial Site Garran
Belgium Clinical Trial Site Brussels
France Clinical Trial Site Bron
France Clinical Trial Site Lyon
Israel Clinical Trial Site Haifa
Israel Clinical Trial Site Nahariya
Italy Clinical Trial Site Rome
Jordan Clinical Trial Site Irbid
Lebanon Clinical Trial Site Beirut
Netherlands Clinical Trial Site Amsterdam
Turkey Clinical Trial Site Yenimahalle
United Arab Emirates Clinical Trial Site Dubai
United States Clinical Trial Site Houston Texas
United States Clinical Trial Site Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Alnylam Pharmaceuticals

Countries where clinical trial is conducted

United States,  Australia,  Belgium,  France,  Israel,  Italy,  Jordan,  Lebanon,  Netherlands,  Turkey,  United Arab Emirates, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cohort A: Percent Change in Plasma Oxalate From Baseline to Month 6 Percent change in plasma oxalate (umol/L) was estimated by an average percent change from baseline across Months 3 through 6. A negative change from Baseline indicates a favorable outcome. For Cohort A, the baseline was defined as the mean of all plasma oxalate level values collected prior to the first dose of lumasiran. Baseline to Month 6
Primary Cohort B: Percent Change in Pre-dialysis Plasma Oxalate From Baseline to Month 6 Percent change in plasma oxalate (umol/L) was estimated by an average percent change from baseline across Months 3 through 6. A negative change from Baseline indicates a favorable outcome. For Cohort B, the baseline is defined as the mean of the last four pre-dialysis plasma oxalate samples collected prior to the first dose of lumasiran. In Cohort B, only pre-dialysis samples are utilized. Baseline to Month 6
Secondary Cohort B: Percent Change in Plasma Oxalate Area Under the Curve From 0-24 Hours [AUC(0-24)] Between Dialysis Sessions From Baseline to Month 6 Percent change in plasma oxalate AUC(0-24) was estimated by an average percent change from baseline across Months 3 through 6. A negative change from Baseline indicates a favorable outcome. Baseline was defined as the mean value of all valid AUC (µmol/L/24h) profiles being computed prior to the first dose of lumasiran. Baseline to Month 6
Secondary Absolute Change in Plasma Oxalate From Baseline to Month 6 Absolute change in plasma oxalate was estimated by an average absolute change from baseline across Months 3 through 6. A negative change from Baseline indicates a favorable outcome. For Cohort A, the baseline was defined as the mean of all plasma oxalate level values collected prior to the first dose of lumasiran; for Cohort B, the baseline was defined as the mean of the last 4 pre-dialysis plasma oxalate level values collected prior to the first dose of lumasiran. In Cohort B patients, the plasma oxalate baseline was similarly defined except that the values obtained from the plasma oxalate profile assessment visits only included the pre-dialysis sample collected per visit. Baseline to Month 6
Secondary Cohort A: Absolute Change in 24-hour Urinary Oxalate Excretion Corrected for Body Surface Area (BSA) From Baseline to Month 6 Absolute change in 24-hour urinary oxalate excretion corrected for BSA was estimated by an average absolute change from baseline across Months 3 through 6. Only valid urine samples without any non-protocol-related issues were included in the analysis. A negative change from Baseline indicates a favorable outcome. Baseline is defined as the median of all valid 24-hr urine assessments collected prior to the first dose date/time of lumasiran without any non-protocol-related sample issues. Baseline to Month 6
Secondary Cohort A: Percent Change in 24-hour Urinary Oxalate Excretion Corrected for Body Surface Area (BSA) From Baseline to Month 6 Percent change in 24-hour urinary oxalate excretion corrected for BSA was estimated by an average percent change from baseline across Months 3 through 6. Only valid urine samples without any non-protocol-related issues were included in the analysis. A negative change from Baseline indicates a favorable outcome. Baseline is defined as the mean of all assessments prior to the first dose date/time of lumasiran. Baseline to Month 6
Secondary Cohort A: Absolute Change in Spot Urinary Oxalate:Creatinine Ratio From Baseline to Month 6 Absolute change in spot urinary oxalate:creatinine ratio was estimated by an average absolute change from baseline across Months 3 through 6. A negative change from Baseline indicates a favorable outcome. Baseline was defined as the mean of all assessments prior to the first dose date/time of lumasiran. Baseline to Month 6
Secondary Cohort A: Percent Change in Spot Urinary Oxalate:Creatinine Ratio From Baseline to Month 6 Percent change in spot urinary oxalate:creatinine ratio was estimated by an average percent change from baseline across Months 3 through 6. A negative change from Baseline indicates a favorable outcome. Baseline was defined as the mean of all assessments prior to the first dose date/time of lumasiran. Baseline to Month 6
Secondary Change in Quality of Life As Assessed by Pediatric Quality of Life Inventory (PedsQL) Total Score From Baseline to Month 6 in Patients >=2 to 18 Years of Age at Time of Informed Consent Peds-QL is a modular approach to measuring quality of life (QOL) in healthy children and adolescents and those with acute and chronic health conditions. The PedsQL Generic Core Scales contain 23 items designed to measure core domains of health (physical, emotional, and social functioning) and role (school functioning). Scores are summarized as Total Scale Score, Physical Health Summary Score, and Psychosocial Health Summary Score. The Total Scale Score will be reported for this study. The PedsQL will be completed by patients (or caregivers, as appropriate) who are =2 to <18 years of age at the time of consent. Total score range: 0 - 100, with higher scores indicating better health-related quality of life (HRQoL). Baseline is defined as last non-missing value collected prior to the first dose of lumasiran. Baseline to Month 6
Secondary Change in Quality of Life As Assessed by Kidney Disease and Quality of Life (KDQOL) Scores From Baseline to Month 6 in Patients =18 Years of Age at Time of Informed Consent The KDQOL questionnaire is used to assess 3 core domains of kidney disease including: burden, symptoms/problems, and effects of kidney disease on daily life. The KDQOL subscales (Burden of Kidney Disease, Effect of Kidney Disease on Daily Life, and Symptoms and Problems of Kidney Disease), and the accompanying Short Form-12 (SF-12) Physical Component Summary and Mental Component Summary will be assessed for this study. These will be completed by patients who are =18 years of age at the time of consent. Score range (per domain): 0 - 100; higher scores indicate better HRQoL. Baseline is defined as last non-missing value collected prior to the first dose of lumasiran. Baseline to Month 6
Secondary Maximum Plasma Concentration (Cmax) of Lumasiran Cmax is the highest concentration of lumasiran in the plasma after a dose is given. Day 1; Month 6
Secondary Time to Maximum Plasma Concentration (Tmax) of Lumasiran Tmax is the time it takes for lumasiran to reach the maximum concentration (Cmax) after administration. Day 1; Month 6
Secondary Elimination Half-life (t½ß) of Lumasiran t½ß is the time it takes for the concentration of the drug in the plasma to be reduced by 50%. Day 1; Month 6
Secondary Area Under the Concentration-time Curve From 0 to 24 Hours [AUC(0-24)] for Lumasiran AUC(0-24) is the area under the plasma concentration-time curve over the last 24-h dosing interval. Day 1; Month 6
Secondary Apparent Clearance (CL/F) of Lumasiran CL/F is the rate at which lumasiran is eliminated from the body. Day 1; Month 6
Secondary Apparent Volume of Distribution (V/F) of Lumasiran V/F is the propensity of lumasiran to either remain in the plasma or redistribute to other tissues. Day 1; Month 6
Secondary Percent Change in Plasma Oxalate Area Under the Curve From 0-24 Hours [AUC(0-24)] Between Dialysis Sessions From Baseline to Month 60 Baseline to Month 60
Secondary Absolute Change in Plasma Oxalate From Baseline to Month 60 Baseline to Month 60
Secondary Absolute Change in 24-hour Urinary Oxalate Excretion Corrected for Body Surface Area (BSA) From Baseline to Month 60 Baseline to Month 60
Secondary Percent Change in 24-hour Urinary Oxalate Excretion Corrected for Body Surface Area (BSA) From Baseline to Month 60 Baseline to Month 60
Secondary Absolute Change in Spot Urinary Oxalate:Creatinine Ratio From Baseline to Month 60 Baseline to Month 60
Secondary Percent Change in Spot Urinary Oxalate:Creatinine Ratio From Baseline to Month 60 Baseline to Month 60
Secondary Change in Quality of Life As Assessed by Pediatric Quality of Life Inventory (PedsQL) Total Score From Baseline to Month 60 in Patients >=2 to 18 Years of Age at Time of Informed Consent Peds-QL is a modular approach to measuring quality of life (QOL) in healthy children and adolescents and those with acute and chronic health conditions. The PedsQL Generic Core Scales contain 23 items designed to measure core domains of health (physical, emotional, and social functioning) and role (school functioning). Scores are summarized as Total Scale Score, Physical Health Summary Score, and Psychosocial Health Summary Score. The Total Scale Score will be reported for this study. The PedsQL will be completed by patients (or caregivers, as appropriate) who are =2 to <18 years of age at the time of consent. Total score range: 0 - 100, with higher scores indicating better health-related quality of life (HRQoL). Baseline is defined as last non-missing value collected prior to the first dose of lumasiran. Baseline to Month 60
Secondary Change in Quality of Life As Assessed by Kidney Disease and Quality of Life (KDQOL) Scores From Baseline to Month 60 in Patients =18 Years of Age at Time of Informed Consent The KDQOL questionnaire is used to assess 3 core domains of kidney disease including: burden, symptoms/problems, and effects of kidney disease on daily life. The KDQOL subscales (Burden of Kidney Disease, Effect of Kidney Disease on Daily Life, and Symptoms and Problems of Kidney Disease), and the accompanying Short Form-12 (SF-12) Physical Component Summary and Mental Component Summary will be assessed for this study. These will be completed by patients who are =18 years of age at the time of consent. Score range (per domain): 0 - 100; higher scores indicate better HRQoL. Baseline is defined as last non-missing value collected prior to the first dose of lumasiran. Baseline to Month 60
Secondary Percent Change in Plasma Oxalate From Baseline to End of Study Baseline to Month 60
Secondary Change in Nephrocalcinosis From Baseline to End of Study Nephrocalcinosis will be assessed by renal ultrasound. Baseline to Month 60
Secondary Change in Frequency of Dialysis From Baseline to End of Study Baseline to Month 60
Secondary Change in Mode of Dialysis From Baseline to End of Study Modes of dialysis are defined as hemodialysis and peritoneal dialysis. Baseline to Month 60
Secondary Change in Frequency of Renal Stone Events From Baseline to End of Study Baseline to Month 60
Secondary Change in Renal Function Assessed by Estimated Glomerular Filtration Rate (eGFR) From Baseline to End of Study Baseline to Month 60
Secondary Change in Measures of Systemic Oxalosis From Baseline to End of Study Systemic oxalosis will be assessed in cardiac, skeletal, ophthalmologic, and dermatologic systems. Baseline to Month 60
See also
  Status Clinical Trial Phase
Withdrawn NCT00875823 - International Registry for Primary Hyperoxaluria N/A
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Completed NCT02340689 - Primary Hyperoxaluria Mutation Genotyping/Phenotyping
Completed NCT00638703 - Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients Phase 2/Phase 3
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Completed NCT03819647 - Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria Phase 2
Recruiting NCT02026388 - Rare Kidney Stone Consortium Biobank
Completed NCT02000219 - Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on Dialysis Phase 2
Recruiting NCT05843851 - Genetic Newborn Screening for Cystinosis and Primary Hyperoxaluria N/A
Recruiting NCT00588562 - Rare Kidney Stone Consortium Patient Registry
Completed NCT03391804 - Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia Phase 2
Completed NCT03116685 - A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria Phase 3
Recruiting NCT05107830 - Phenotyping of Primary Hyperoxaluria
Recruiting NCT05001269 - Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function Phase 2
Completed NCT03392896 - Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria Phase 1
Completed NCT02012985 - Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary Hyperoxaluria Phase 1/Phase 2
Completed NCT01037231 - Phase 2/3 Oxabact Study Phase 2/Phase 3
Completed NCT00589225 - Primary Hyperoxaluria Mutation Genotyping Phase 1
Completed NCT02124395 - Health-related Quality of Life in Rare Kidney Stone
Completed NCT03350451 - An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1 Phase 2